Arena Pharmaceuticals (ARNA) On 10-Day Winning Streak Ahead of FDA Approval
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
While stocks are broadly selling-off, Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is beasting higher. The stock is now up for tenth straight session.
Shares are up another 9 percent Thursday, on volume of over 50 million shares. Shares are up 78 percent since this latest run started on June 8th.
The surge comes in anticipation of FDA approval for obesity drug Lorcaserin, which is widely expected on June 27th - baring any last-minute delay.
With 35.7% of U.S. adults obese (as of 2010), according to the CDC, the market for Lorcaserin would seem massive. In 2008, medical costs associated with obesity were estimated at $147 billion. Both figures have likely only surged higher since.
Shares are up another 9 percent Thursday, on volume of over 50 million shares. Shares are up 78 percent since this latest run started on June 8th.
The surge comes in anticipation of FDA approval for obesity drug Lorcaserin, which is widely expected on June 27th - baring any last-minute delay.
With 35.7% of U.S. adults obese (as of 2010), according to the CDC, the market for Lorcaserin would seem massive. In 2008, medical costs associated with obesity were estimated at $147 billion. Both figures have likely only surged higher since.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E Corp, Edison Spike; California Assembly Won't Take Vote On Utility Wildfire Bill
- Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
- S&P Weighs Multibillion-Dollar Spinout of Data Platform CapIQ - Bloomberg
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
